Secondary prevention of myocardial infarction: effectiveness assessment in primary healthcare settings
Abstract
Aim. To evaluate the effectiveness of ambulatory secondary prevention among patients after myocardial infarction (MI). Material and methods. In total, 208 ambulatory medical histories of patients, examined at the cardiology dispanser and three polyclinics, were analysed. All patients, aged 45-75 years, previously had an MI, with or without Q wave (1 month — 1 year ago). In addition, all patients underwent clinical interview. Results. A very low level of non-pharmaceutical therapy compliance was observed. Every fourth cardiology dispanser patient and every second polyclinic patient were not compliant to dietary recommendations; 47 % and 35,2 %, respectively, had low physical activity, and every second male patient was a current smoker. Cardiology dispanser and polyclinic doctors prescribed anti-aggregants to 86 % and 75 % of their patients, respectively. For beta-adrenoblockers, the respective percentages were 86 % and 52,8 %, and for statins — 87 % and 21,3 %. Lipid profile assessment was regularly performed in 49 % of the cardiology dispanser patients. In 11 %, lipid profile was assessed irregularly, and in 40 % of the cases, only total cholesterol level was measured. Conclusion. The study results suggest low compliance of primary healthcare patients to non-pharmaceutical therapy. Polyclinic doctors demonstrated inadequate knowledge on pharmacotherapy potential in treating postMI patients.
About the Authors
Yu. I. Nesterov
Kemerovo State Medical Academy. Kemerovo
Russian Federation
Russian Federation
S. A. Makarov
Kemerovo State Medical Academy. Kemerovo
Russian Federation
Russian Federation
O. S. Krestova
Kemerovo State Medical Academy. Kemerovo
Russian Federation
Russian Federation
References
1. Оганов Р.Г., Погосова Г.В. Современная стратегия первичной профилактики и лечения сердечно-сосудистых заболеваний. Кардиология 2007; 12: 4-9.
2. Руководство по амбулаторно-поликлинической кардиологии. Под ред. Ю. Н. Беленкова, Р. Г. Оганова. М: ГоэтарМедиа 2007; 400 с.
3. British Heart Foundation. 2006 Coronary heart disease statistics. http: www.heartstats.org/ datapage.asp? id=6799.
4. Гафаров В.В., Гафарова А.В., Благина М.Ю. Программа ВОЗ “Регистр острого инфаркта миокарда”: 25-летие эпидемиологического исследования инфаркта миокарда в России (1977 – 2001). Кардиология 2005; 8: 48-50.
5. Блужас И., Сталиорайтите Е., Пангоните Д., Казлаускайте Д. Внезапная внебольничная коронарная смерть – отдельный независимый острый коронарный синдром или вид смерти от ишемической (коронарной) болезни сердца? Кардиология 2003; 7: 41-8.
6. Taylor RS, Bolli R, Dawn B, et al. Exercise-based rehabilitation for patients with coronary heart disease: review and metaanalysis of randomized controlled trials. Am J Med 2005; 352 (13): 1293- 304.
7. Диагностика и коррекция нарушений липидного обмена с цельюпрофилактики и лечения атеросклероза. Российские рекомендации. Москва 2007 г. Приложение к ж Кардиоваск тер профил. 8.
8. Sdrinqola S, Nakaqawa K, Meurin P, et al. Combined intense and pharmacoloqic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowerinq druqs in coronary artery disease. JACC 2003; 41: 263-72.
9. Вторичная профилактика сердечно-сосудистых заболеваний. Национальный проект “Здоровье”. От редакции. Сердце 2007; 1(33): 4-24.
10. Critchley JA, Capewell S. Mortality risk reduction associatrd with smoking cessation in patients with coronary heart disease a systematic review. JAMA 2003; 290: 86-97.
11. Jolliffee JA, Rees K, Taylor RS, et al. Exercise – based rehabilitation for coronary heart disease Cochrane Database Syst Rev 2001; 1: CDOO 1800.
12. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-16.
13. Джаиани Н.А., Терещенко С.Н. Вторичная профилактика инфаркта миокарда: фармакотерапевтические аспекты. Справоч поликлин врача 2007; 2: 19-23.
14. Чазов Е.И. Пути снижения смертности от сердечно-сосудистых заболеваний. Тер архив 2008; 8: 11-6.
15. Оганов Р. Г., Масленникова Г. Я. Профилактика сердечно-сосудистых и других неинфекционных заболеваний – основа улучшения демографической ситуации в России. Кардиоваск тер и профил 2005; 3 (1): 4-9.
16. Fung JW, Yu CM, Kum CL, et al. Role of beta-blocker therapy in heart failure and atrial fibrillation. Card Electrophysiol Rev 2003; 7(3): 236-42.
17. Рудакова А.В. Статины в терапии ишемической болезни сердца: фармакоэкономические аспекты. Сердце 2008; 4(42): 227-33.
18. Фитилев С.В., Левин А.Н., Титарова Ю.Ю. и др. Первичная и вторичная профилактика атеросклероза и его осложнений у пациентов с артериальной гипертонией в амбулаторной практике г. Москвы (фармакоэпидемиологическое исследование). Мат Межд конгр “Развитие фармакономики и фармакоэпидемиологии в Российской Федерации”. Москва 2006; 223.
19. Fonarow GC. In-Hospital Initiation of Statin Therapy in Acutо Coronary Syndromes Maхimizing: the Tarly and Longterm Benefts. Chest 2005; 128(5): 3641-51.
Review
For citations:
Nesterov Yu.I., Makarov S.A., Krestova O.S. Secondary prevention of myocardial infarction: effectiveness assessment in primary healthcare settings. Cardiovascular Therapy and Prevention. 2010;9(5):12-17. (In Russ.)
Views:
5415
Email this article 
